Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $51.5 million versus the consensus estimate of $53.1 million.

GUIDANCE:

Meridian Bioscience sees FY2019 EPS of $0.74-$0.76, versus the consensus of $0.76.

• Net revenues Flat-2% growth

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.